A New Look at the Recent Clinical Advancements Made in Moderate-to- Severe Atopic Dermatitis: Online CME Activity

About
Faculty
Learning Objectives
Intended Audience
Accreditation Statement
Credit Designation Statement
Disclosure
Disclaimer

This CME activity was recording at the 2020 Fall Clinical Dermatology Conference. It is supported by an educational grant from Pifzer.

Seemal Desai, MD

Faculty

Clinical Assistant Professor
Department of Dermatology
University of Texas Southwestern Medical Center
Dallas, TX

Upon completion of this activity, the participant should be better able to:

Understand the immune/inflammatory cascade and their role in pathophysiology of psoriasis and other dermatologic conditions
Become familiar with the current and emerging JAK inhibitor therapies
Discern the clinical relevance of and indications for the JAK inhibitors and TYK2 inhibitors for psoriasis
Understand the safety and efficacy profile of the various JAK inhibitors
Recognize the clinical advantages and limitations of different JAKs and TYK2-inhibitor therapy for patients with psoriasis and other related immune-related diseases

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients with atopic dermatitis and other related diseases.

The University of Nevada Reno School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™.

Seemal Desai, MD

Consultant/Independent Contractor: Abbvie Inc., Dermavant Sciences, Inc., Novan, SkinMedica, Symbio, Watson
Grant/Research Support: Dermavant Sciences, Inc., Menlo, Pfizer, Skinceuticals
Speakers Bureau: Pfizer, Skinceuticals

This activity is supported by an educational from Pfizer.

[fc+323]